Suchergebnisse - "Shuster, Diana L"

PubPharm (26)

1

Framework for the Design of Cannabis-Mediated Phase I Drug-Drug Interaction Studies

enthalten in: Current reviews in clinical and experimental pharmacology | 2022

von Shuster, D. | Pastino, G. | Cerneus, D.

2

Pharmacodynamics of Glyburide, Metformin, and Glyburide/Metformin Combination Therapy in the Treatment of Gestational Diabetes Mellitus

enthalten in: Clinical pharmacology and therapeutics | 2020

von Shuster, D. | Shireman, L. | Ma, X. | +17

3

Pharmacodynamics of Metformin in Pregnant Women With Gestational Diabetes Mellitus and Nonpregnant Women With Type 2 Diabetes Mellitus

enthalten in: Journal of clinical pharmacology | 2020

von Shuster, D. | Shireman, L. | Ma, X. | +17

4

Pharmacodynamics of Glyburide, Metformin, and Glyburide/Metformin Combination Therapy in the Treatment of Gestational Diabetes Mellitus

enthalten in: Clinical Pharmacology & Therapeutics | 2020

von Shuster, D. | Shireman, L. | Ma, X. | +17

5

Pharmacodynamics of Metformin in Pregnant Women With Gestational Diabetes Mellitus and Nonpregnant Women With Type 2 Diabetes Mellitus

enthalten in: The Journal of Clinical Pharmacology | 2020

von Shuster, D. | Shireman, L. | Ma, X. | +17

6

Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease

enthalten in: Kidney international reports | 2019

von Bernstein, D. | Tran, A. | Martin, P. | +9

7

Effects of chronic kidney disease stage 4, end-stage renal disease, or dialysis on the plasma concentrations of ombitasvir, paritaprevir, ritonavir, and dasabuvir in patients with chronic HCV infection : pharmacokinetic analysis of the phase 3 RUBY-I and RUBY-II trials

enthalten in: European journal of clinical pharmacology | 2019

von Shuster, D. | Menon, R. | Ding, B. | +6

8

Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir and With or Without Ribavirin for Adolescents With HCV Genotype 1 or 4

enthalten in: Hepatology communications | 2018

von Leung, D. | Wirth, S. | Yao, B. | +15

9

Effects of chronic kidney disease stage 4, end-stage renal disease, or dialysis on the plasma concentrations of ombitasvir, paritaprevir, ritonavir, and dasabuvir in patients with chronic HCV infection: pharmacokinetic analysis of the phase 3 RUBY-I and RUBY-II trials

enthalten in: European journal of clinical pharmacology | 2018

von Shuster, D. | Menon, R. | Ding, B. | +6

10

Effects of chronic kidney disease stage 4, end-stage renal disease, or dialysis on the plasma concentrations of ombitasvir, paritaprevir, ritonavir, and dasabuvir in patients with chronic HCV infection: pharmacokinetic analysis of the phase 3 RUBY-I and RUBY-II trials

enthalten in: European journal of clinical pharmacology | 2018

von Shuster, D. | Menon, R. | Ding, B. | +6